The aim was to determine the effects of dulaglutide, a synthetic once-weekly, injectable human glucagon-like peptide 1 analogue that lowers blood glucose, body weight, appetite and blood pressure, on cardiovascular outcomes. People with type 2 diabetes, aged ≥50 years, with glycated haemoglobin (HbA1c) ≤9.5%, and either a previous cardiovascular event, evidence of cardiovascular disease or ≥2 cardiovascular risk factors were randomly allocated to a weekly subcutaneous injection of either dulaglutide (1.5 mg) or placebo and followed within the ongoing Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial every 3 to 6 months. The primary cardiovascular outcome is the first occurrence of the composite of cardiovascular death or non-fatal myocardial infarction or non-fatal stroke. Secondary outcomes include each component of the primary composite cardiovascular outcome, a composite clinical microvascular outcome comprising retinal or renal disease, hospitalization for unstable angina, heart failure requiring hospitalization or an urgent heart failure visit, and all-cause mortality. Follow-up will continue until the accrual of 1200 confirmed primary outcomes. Recruitment of 9901 participants (mean age 66 years, 46% women) occurred in 370 sites located in 24 countries over a period of 2 years. The mean duration of diabetes was 10 years, mean baseline HbA1c was 7.3%, and 31% had prior cardiovascular disease. The REWIND trial's international scope, high proportion of women, high proportion of people without prior cardiovascular disease and inclusion of participants whose mean baseline HbA1c was 7.3% suggests that its cardiovascular and safety findings will be *clinicaltrials.gov: NCT01394952
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The REWIND trial is funded by Eli Lilly and Company directly relevant to the typical middle-aged patient seen in general practice throughout the world.
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| INTRODUCTION
The incidence of cardiovascular events in people with type 2 diabetes is about twice as high as it is in similar individuals without type 2 diabetes. 1 This higher incidence is caused by a number of risk factors related to the causes and consequences of dysglycaemia, 2 obesity, dyslipidaemia, hypertension and endothelial damage or dysfunction. 3, 4 Such abnormalities have provided the basis for an array of randomized controlled trials on the effect of both glucometabolic and non-glucometabolic interventions on cardiovascular events in people with diabetes. To date, trials with non-glucometabolic therapies have
shown that statins, 5 renin angiotensin system modulators, 6 ,7 other blood pressure-lowering agents, 8, 9 and a Mediterranean diet 10 can reduce cardiovascular events, whereas lifestyle interventions focused on weight reduction have, to date, had a neutral effect. 11 Trials of glucometabolic therapies in people with diabetes have shown that intensive glucose-lowering modestly reduces cardiovascular outcomes, mainly because of an effect on ischaemic heart disease, [12] [13] [14] [15] and has an uncertain effect on mortality. 16 Other studies that focused on drug effects rather than glucose-lowering effects have
shown that insulin-sensitizing approaches have the same effect on cardiovascular outcomes as insulin-providing approaches, 17 pioglitazone has a mixed effect on cardiovascular outcomes, 18 basal insulin 19 and dipeptidyl peptidase-4 (DPP-4) inhibitors [20] [21] [22] have a neutral effect on cardiovascular outcomes, and one sodium-glucose co-transporter-2 (SGLT2) inhibitor, empagliflozin, reduces cardiovascular and total mortality as well as hospitalization for heart failure. 23 Glucagon-like peptide-1 (GLP-1) receptor agonists are analogues of natural GLP-1, a gastrointestinal hormone which is secreted in response to food intake and increases insulin secretion in response to glucose, reduces glucagon secretion, reduces appetite, and slows gastric emptying. 24 The biological effects of this hormone on the circulatory system suggest that it may also have salutary cardiovascular effects. Because natural GLP-1 has a very short half-life, analogues that resist degradation and that are given once (liraglutide, lixisenatide) or twice (exenatide) daily, weekly (long-acting exenatide, dulaglutide, semaglutide, albiglutide) or less frequently (implanted subcutaneous exenatide pump) have been developed. 25 Clinical trials of these analogues have shown that these drugs lower glucose levels without promoting hypoglycaemia, modestly lower blood pressure, increase heart rate by 2 to 4 beats/min, and promote modest weight loss. 24 The effects of some of these agents on cardiovascular outcomes have also been reported: once-daily lixisenatide had a neutral effect on cardiovascular outcomes after a diagnosis of acute coronary syndrome in 6068 people with a mean age of 60 years, whose mean baseline glycated haemoglobin (HbA1c) was 7.7% and who were treated for a median of 2.1 years
26
; once-daily liraglutide reduced cardiovascular events as well as cardiovascular deaths in 9340 people with a mean age of 64 years and a mean baseline HbA1c of 8.7% and who were followed for a median of 3.8 years
27
; and once-weekly semaglutide reduced cardiovascular events and stroke in 3297 people with a mean age of 65 years and a mean baseline HbA1c of 8.7% and who were followed for a median of 2.1 years.
Dulaglutide is a synthetic analogue of human GLP-1 that structurally comprises 2 GLP-1 receptor agonist molecules that are covalently linked to 1 IgG4 heavy chain by a small peptide linker. It has pharmacological half-life of 5 days, which allows it to be administered as a weekly subcutaneous injection. 28 Clinical trials have shown that doses of 0.75 to 1.5 mg weekly reduce HbA1c as well as body weight, appetite and blood pressure. 29 A meta-analysis of randomized controlled trials comprising 6010 individuals with diabetes followed for a median of~1 year reported a neutral effect on the first occurrence of non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina, or death from cardiovascular causes. 30 When given alone the drug does not cause hypoglycaemia; however, like other GLP-1 receptor agonists, it can cause nausea and diarrhoea in up to 10% of individuals. Dulaglutide's effects on glucose, blood pressure and weight, 28 together with evidence that GLP-1 receptors are expressed in the heart and that GLP-1 has anti-atherosclerotic and anti-inflammatory effects in animal studies, all suggest its potential for cardiovascular benefits, and support its assessment in a longterm cardiovascular outcomes trial.
| METHODS
The Ethics review boards responsible for each participating institution approved the protocol. After providing written, informed consent, participants were stratified by site and randomly allocated using blocks of 4 to either a weekly subcutaneous injection of dulaglutide ease, hospitalization for unstable angina, heart failure requiring hospitalization or an urgent heart failure visit, and all-cause mortality.
These and other prespecified clinical and biochemical outcomes are noted in Table 2 . Safety outcomes include acute pancreatitis, serious and severe gastrointestinal pain, pancreatic, thyroid or other cancers, severe hypoglycaemia, hypersensitivity reactions, and other liver, renal or cardiovascular events as well as drug discontinuation.
All deaths and cardiovascular, pancreatic and thyroid events (i.e. both efficacy and safety outcomes) are adjudicated by an external adjudication committee, which is blinded to treatment allocation. Participants will continue to be followed until the trial is completed regardless of whether or not they have had a study outcome or whether or not they continue to take study medication. Unless permission is explicitly revoked, vital status at the end of the trial will be obtained on all randomized participants whenever possible.
The REWIND trial is sponsored by Eli Lilly, site management and 
| Sample size
Sample size calculations were based on a 3-year recruitment period, an anticipated primary outcome event rate of 2% per year in the control group, annual dropout rate of 0.15%, and a 2-sided type I error of 5%. These assumptions indicated that recruitment of 9600 patients would result in a total of 1200 participants with at least 1 primary cardiovascular outcome over a maximum follow-up period of 8 years, and would provide 90% power to detect a hazard ratio of 0.82 for cardiovascular events. Follow-up will end after 1200 participants have had a primary cardiovascular outcome confirmed by adjudication.
| Statistical analysis
All efficacy and safety analyses will be conducted using an intentionto-treat approach that includes all randomized participants regardless of adherence. Baseline continuous variables will be summarized as either means or medians with their standard deviations or interquartile ranges, and categorical variables will be summarized as the number and percentage. The effect of the intervention on the time to the first occurrence of the primary outcome will be analysed using Cox proportional hazards models with the only independent variable being allocation to dulaglutide vs placebo. The proportional hazard assumption will be assessed graphically. Kaplan-Meier curves will also be generated along with log-rank P values. The incidence rate per 100 personyears will be calculated for each treatment group for all key outcomes.
All secondary outcomes will be analysed in a predetermined order defined by a graphical approach to control the overall type I error. [33] [34] [35] If the null hypothesis of no effect is rejected for the primary outcome, the graphical testing approach allocates the α parsimoniously for each secondary outcome. A detailed description of the graphical approaches is provided in the online supporting information.
All subgroup analyses will be considered exploratory and will be conducted only for outcomes where the event number is at least 50.
Subgroups to be examined include: gender; age below vs at or above the median; duration of diabetes <5 years, 5 to 9.9 years and Tables 3 and 4, the mean age of participants (46% women) was 66 years, the mean BMI was 32 kg/m 2 and 31% had a history of cardiovascular disease (defined as a history of MI, ischaemic stroke, revascularization, hospitalization for unstable angina with concordant new ischaemic ECG changes, or a positive stress test with concordant imaging). In addition, 93% had a history of hypertension, 9% had a history of prior heart failure, and the mean blood pressure was 137/78 mmHg. The mean reported duration of diabetes was 10 years, 24% of participants were taking insulin, 81% were taking metformin, 57% were on a sulphonylurea, and the mean baseline HbA1c was 7.3%. An angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) was used by 81% of participants, 45% were taking a β-blocker, 66% were taking a statin at baseline, 51% were on acetylsalicylic acid, 8% were on other antiplatelet agents, and the mean baseline LDL cholesterol was 2.56 nmol/L.
| DISCUSSION
REWIND is a randomized placebo-controlled trial measuring the cardiovascular effects of once-weekly dulaglutide in patients with type 2 diabetes. This trial's international scope, high proportion of women, high proportion of people without prior cardiovascular disease, and inclusion of participants whose mean baseline HbA1c was 7.3% means that its results will be directly relevant to the average middleaged patient with diabetes seen in many programmes throughout the world. Its focus on the "typical" middle-aged patient with type 2 diabetes distinguishes it from the other GLP-1 receptor agonist cardiovascular outcomes trials reported to date 26, 27, 36 that are summarized in Table 5 , which have focused on high-risk patients either after an acute coronary syndrome event or with a very high prevalence of prior cardiovascular disease, and with higher levels of HbA1c at baseline.
The REWIND trial is designed to determine whether people allocated to dulaglutide have a lower hazard of cardiovascular events than those allocated to placebo, and the planned accrual of 1200 first primary outcomes during a fairly long follow-up period of 7 to 8 years will provide high power to detect a clinically relevant 18%
reduction. This high number of outcomes also ensures that there will be narrow confidence intervals around the estimated effect size.
REWIND is also explicitly assessing potential side effects of dulaglutide and its effect on a large variety of clinically important outcomes including all-cause mortality, renal disease, hospitalizations for heart failure or angina, cancer (including thyroid cancer), and pancreatitis. Moreover, its predefined graphical testing strategy will optimize the ability to identify those components of the primary and secondary outcomes that are most affected by dulaglutide. These considerations suggest that REWIND will provide a comprehensive assessment of the clinical effects of the drug and will clearly facilitate clinicians' ability to practice evidence-based care of patients with type 2 diabetes who are typical of those seen on a day-to-day basis.
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